Adaptive Biotechnologies (ADPT) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adaptive Biotechnologies (ADPT) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 83.1% versus a gain of 28.6%. Over five years, ADPT leads with a -21.6% price change compared with -57.9% for DNLI. Adaptive Biotechnologies is the larger company by market cap ($4.07 billion vs $2.96 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADPT | DNLI |
|---|---|---|
| Share price | $25.51 | $18.52 |
| Market cap | $4.07B | $2.96B |
| 1-day change | -2.93% | -3.37% |
| YTD return | +61.82% | +16.05% |
| 1-year return | +83.14% | +28.59% |
| 5-year return | -21.55% | -57.95% |
| EPS (TTM) | $-0.41 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $276.98M | $0 |
| Revenue growth (YoY) | +54.77% | — |
| Net income (latest FY) | $-59.50M | $-512.54M |
| Gross margin | 74.24% | — |
| Operating margin | -20.62% | — |
| Net margin | -21.48% | — |
| 52-week high | $30.74 | $27.30 |
| 52-week low | $12.00 | $13.75 |
| Distance from 52-week high | -17.01% | -32.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +10.98% | +94.76% |
| Average volume | 2.38M | 1.61M |
| Shares outstanding | 159.60M | 159.85M |
| Employees | 624 | 503 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADPT has outperformed DNLI by 54.5 percentage points over the past year.
About Adaptive Biotechnologies
ADPT stock →Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
ADPT vs DNLI FAQ
Which is bigger, Adaptive Biotechnologies or Denali Therapeutics?
Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.07B compared with $2.96B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, ADPT or DNLI?
ADPT returned +83.14% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Adaptive Biotechnologies and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.